2 weeks Ago By ABMN Staff
Kampmann Melissa S. cut its position in shares of Hologic, Inc. ( NASDAQ:HOLX – Free Report ) by 0.
6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,375 shares of the medical equipment provider’s stock after selling 215 shares during the quarter. Hologic accounts for about 2.
0% of Kampmann Melissa S.’s portfolio, making the stock its 27th biggest holding. Kampmann Melissa S.
’s holdings in Hologic were worth $2,775,000 at the end of the most recent reporting period. A number of other hedge funds and other institutional investors have also bought and sold shares of HOLX. Innealta Capital LLC bought a new stake in Hologic during the 2nd quarter worth about $25,000.
iA Global Asset Management Inc. bought a new stake in Hologic during the first quarter worth about $37,000. Sunbelt Securities Inc.
bought a new stake in Hologic during the second quarter worth about $37,000. Cranbrook Wealth Management LLC acquired a new position in Hologic during the second quarter valued at approximately $47,000. Finally, Mather Group LLC.
bought a new position in Hologic in the first quarter valued at approximately $48,000. Institutional investors and hedge funds own 94.73% of the company’s stock.
Hologic Trading Up 0.9 % Shares of Hologic stock opened at $80.82 on Monday.
Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.
67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.
32 and a current ratio of 3.99. The firm has a 50-day moving average of $81.
08 and a 200-day moving average of $77.29. The stock has a market cap of $18.
86 billion, a PE ratio of 41.23, a PEG ratio of 2.58 and a beta of 0.
98. Insiders Place Their Bets In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.
99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.
24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website . In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th.
The shares were sold at an average price of $83.11, for a total value of $39,560.36.
Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at $310,415.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.
07. Following the sale, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24.
The disclosure for this sale can be found here . Insiders have sold a total of 18,280 shares of company stock worth $1,469,973 in the last 90 days. Company insiders own 1.
75% of the company’s stock. Wall Street Analysts Forecast Growth HOLX has been the topic of a number of analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $82.
00 price objective on shares of Hologic in a research note on Friday, August 16th. Stephens restated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th.
JPMorgan Chase & Co. raised their target price on shares of Hologic from $91.00 to $95.
00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Evercore ISI lifted their price target on Hologic from $76.00 to $78.
00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, September 17th.
Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $87.60.
View Our Latest Stock Report on HOLX Hologic Company Profile ( Free Report ) Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Stories Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. ( NASDAQ:HOLX – Free Report ).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter ..
